Back to search

Peptide record

TPDB43135

B1-Ala14 Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB43135
B1-Ala14
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
VKRFKKFFRKLKKAV-NH2
Physicochemical Analysis
C94H159N27O16
NDCEQGHIMPSTWY
K
1923.47
12.46
8
0
7
+8
3.58
-0.667
71.33
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
0
Residue Composition
number
1
A
2
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
1
L
6
K
0
M
3
F
0
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 1 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 6 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
15
C94H159N27O16
1923.47
12.46
+8
3.58
-0.667
Amidation
L
Linear
Free
Antimicrobial and Anticancer
Synthetic analog of B1
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 8.9 µM
Anticancer
8.9 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 8.6 µM
Anticancer
8.6 µM

Target

Leukemia cancer
K-562
Blood

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015